Breast Cancer Clinical Trial
— ZEMYOfficial title:
Feasibility Assessment of an E-Health System (ZEMY) Designed to Manage Symptoms in Patients With Breast Cancer Under Anti-Cancer Treatment
Verified date | July 2019 |
Source | Hoffmann-La Roche |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a three-month open-label, multicenter, interventional, single arm study located in France, designed to assess feasibility and reliability of the e-Health ZEMY software medical device under investigation for use by participants with breast cancer, who are starting an anti-cancer treatment at any stage of the disease, to manage disease symptoms and anti-cancer treatment-related toxicities while at home.
Status | Completed |
Enrollment | 56 |
Est. completion date | April 19, 2019 |
Est. primary completion date | April 19, 2019 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Female patients with breast cancer starting a treatment including oral and/or parenteral anti-cancer drugs (chemotherapy and/or targeted therapies, hormonotherapy) - Inter-cycle duration between hospital visits =14 days (this period of time is estimated to be consistent with a need for support during the home setting period) - Patients shall be prescribed loperamide or any other anti-diarrheic treatment in case of diarrhea and prescription for any medication indicated in case of nausea/vomiting - Able to speak and read French and to use a smartphone embedding ZEMY, in the investigator's judgment - Able to comply with the study protocol, in the investigator's judgment - Patient affiliated to the national social security or beneficiary to such insurance. Exclusion Criteria: - Pregnant - Already enrolled in a clinical study involving experimental medication or eHealth device - Concomitant malignancy - ECOG score >2 - Treated with single hormonotherapy, single surgery or single radiotherapy, immunotherapy. - Patient whose mental state renders her unable to understand the nature, purposes, and consequences of the study - Patient not trained to the use of ZEMY - Patient not trained to take her blood pressure measurement - Patient deprived of her liberty by judicial or administrative order. |
Country | Name | City | State |
---|---|---|---|
France | Centre Francois Baclesse; Oncologie | Caen | |
France | Centre Jean Perrin; Oncologie | Clermont Ferrand | |
France | Hopital Prive Jean Mermoz; Cancerologie | Lyon | |
France | Hopital Saint Louis; Oncologie Medicale | Paris | |
France | Institut du Cancer Coulancy Reims | Reims |
Lead Sponsor | Collaborator |
---|---|
Hoffmann-La Roche |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants Who Successfully Use ZEMY | A participant will be considered as successful in terms of the feasibility of using ZEMY if she has completed at least three symptom reported connections and if the rate of completed symptom reported connections for this participant is = 60%. | 3 months | |
Secondary | Percentage of Appropriate Automatic Messages and Recommendations for Each Symptom by ZEMY, as Evaluated by the Investigator at Each Visit | At Weeks 3, 6, 9, and 12 (Up to 3 months) | ||
Secondary | System Usability Scale Score, Rated by Participants and Healthcare Professionals (HCPs) | At 3 months | ||
Secondary | Satisfaction with ZEMY, Assessed on a Visual Analog Scale by Participants and HCPs | At 3 months | ||
Secondary | Percentage of Participant Answered Entries per ZEMY Requests for Solicited Symptom Information | 3 months | ||
Secondary | Number of Automatic Messages Generated by ZEMY per Participant Over the Study Period | 3 months | ||
Secondary | Number of Automatic Messages Generated by ZEMY per Symptom Over the Study Period | 3 months | ||
Secondary | Number of Recommendations Generated by ZEMY per Participant Over the Study Period | 3 months | ||
Secondary | Number of Recommendations Generated by ZEMY per Symptom Over the Study Period | 3 months | ||
Secondary | Number and Type of Device Deficiencies | Inadequacy of an investigational medical device related to its identity, quality, durability, reliability, safety or performance. This may include malfunctions, use error, or inadequacy in the information supplied by the manufacturer. | 3 months | |
Secondary | Number and Type of Adverse Device Effects | Adverse event related to the use of an investigational medical device. | 3 months | |
Secondary | Number and Type of Serious Adverse Device Effects | Adverse device effect that has resulted in any of the consequences characteristic of a serious adverse event. | 3 months | |
Secondary | Number and Type of Unanticipated Serious Adverse Device Effects | Serious adverse device effect which by its nature, incidence, severity or outcome has not been identified in the current version of the risk analysis report. | 3 months | |
Secondary | Change From Baseline in the EuroQoL 5-Dimension (EQ-5D-5L) Health Questionnaire Score at Each Study Visit | At Baseline and Weeks 3, 6, 9, and 12 (Up to 3 months) | ||
Secondary | Change From Baseline in the European Organization for Research and Treatment of Cancer's Quality-of-Life Questionnaire (EORTC QLQ-30) Score at Each Study Visit | At Baseline and Weeks 3, 6, 9, and 12 (Up to 3 months) | ||
Secondary | Change From Baseline in the European Organization for Research and Treatment of Cancer's Breast Cancer-Specific Quality-of-Life Questionnaire (EORTC QLQ-BR23) Score at Each Study Visit | At Baseline and Weeks 3, 6, 9, and 12 (Up to 3 months) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |